Table of Contents

1. CONTRACEPTIVE DRUGS AND DEVICES ……………………………………….. 1-1
1.1 Contraceptive Drugs……………………………………………………………….. 1-1
1.1.1 Actavis……………………………………………………………………. 1-5
1.1.2 Bayer……………………………………………………………………. 1-13
1.1.3 Janssen Pharmaceuticals/Johnson & Johnson …………… 1-17
1.1.4 Merck & Company………………………………………………….. 1-19
1.1.5 Pfizer ……………………………………………………………………. 1-20
1.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries.. 1-22
1.1.7 Market Forecast …………………………………………………….. 1-24
1.1.8 Competitive Analysis ………………………………………………. 1-25
1.2 Contraceptive Devices…………………………………………………………… 1-30
1.2.1 Actavis………………………………………………………………….. 1-31
1.2.2 Bayer……………………………………………………………………. 1-31
1.2.3 The Female Health Company…………………………………… 1-34
1.2.4 FemCap………………………………………………………………… 1-36
1.2.5 Mayer Laboratories ………………………………………………… 1-37
1.2.6 Merck & Company………………………………………………….. 1-40
1.2.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries.. 1-46
1.2.8 Market Forecast …………………………………………………….. 1-47
1.2.9 Competitive Analysis ………………………………………………. 1-49
1.3 Nonsurgical Sterilization ………………………………………………………… 1-51
1.3.1 Bayer……………………………………………………………………. 1-53
1.3.2 Hologic …………………………………………………………………. 1-53
Exhibit 1-1: 2013, Selected Contraceptive Drugs …………………………………………. 1-6
Exhibit 1-2: 2013, Selected Contraceptive Drugs Under Development ……………. 1-9
Exhibit 1-3: The Average Reduction in Menstrual Bleeding Using Natazia
Over a 90-day Assessment Phase in 2 Studies ………………………… 1-16
Exhibit 1-4: Contraceptive Drugs, Market Forecast, 2012-2017……………………. 1-26
Exhibit 1-5: 2012, Contraceptive Drugs Market, Share by Supplier……………….. 1-29
Exhibit 1-6: 2013, Selected Leading Contraceptive Devices ………………………… 1-32
Exhibit 1-7: 2013, Selected Contraceptive Devices Under Development……….. 1-33
Exhibit 1-8: The Mirena Intrauterine Device ………………………………………………. 1-35
Exhibit 1-9: The FemCap Cervical Cap …………………………………………………….. 1-38
Exhibit 1-10: The NuvaRing Vaginal Contraceptive Ring ………………………………. 1-41
Exhibit 1-11: Efficacy of the NuvaRing Compared to Other
Contraceptive Methods………………………………………………………….. 1-42
Exhibit 1-12: The Implanon Subdermal Contraceptive Implant ………………………. 1-44
Exhibit 1-13: Efficacy of Implanon Compared to Other Contraceptive Methods… 1-45
Exhibit 1-14: The ParaGard Intrauterine Device…………………………………………… 1-48
Exhibit 1-15: Contraceptive Devices, Market Forecast, 2012-2017…………………. 1-50
Exhibit 1-16: 2012, Contraceptive Devices Market, Share by Supplier ……………. 1-52
Exhibit 1-17: The Essure Three-Step Sterilization Procedure ………………………… 1-54
2. FERTILITY DRUGS AND DEVICES…………………………………………………… 2-1
2.1 Selected Fertility Drug Treatments ……………………………………………. 2-2
2.1.1 Actavis……………………………………………………………………. 2-3
2.1.2 EMD Serono/Merck KGaA……………………………………….. 2-15
2.1.3 Ferring Pharmaceuticals………………………………………….. 2-19
2.1.4 Merck & Company………………………………………………….. 2-21
2.1.5 OvaScience…………………………………………………………… 2-23
2.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries.. 2-24
2.1.7 Market Forecast …………………………………………………….. 2-26
2.1.8 Competitive Analysis ………………………………………………. 2-26
2.2 Embryo Transfer Catheters ……………………………………………………. 2-29
2.2.1 CooperSurgical/The Cooper Companies……………………. 2-31
2.2.2 Irvine Scientific/JX Group ………………………………………… 2-31
2.3 Assisted Natural Conception ………………………………………………….. 2-34
3.3.1 Cambridge Temperature Concepts …………………………… 2-34
Exhibit 2-1: 2013, Selected Fertility Drug Therapies …………………………………….. 2-4
Exhibit 2-2: 2013, Selected Immunoassays and Fertility Treatments
Under Development………………………………………………………………… 2-7
Exhibit 2-3: Efficacy of Crinone in Maintaining Full-Term Pregnancies
Following In Vitro Fertilization Embryo Transfer………………………… 2-11
Exhibit 2-4: Efficacy of Crinone in Maintaining Full-Term Pregnancies versus
No Supplemental Progesterone for Luteal Phase Support………….. 2-14
Exhibit 2-5: The Gonal-f RFF Pen ……………………………………………………………. 2-17
Exhibit 2-6: Fertility Drugs, Market Forecast, 2012-2017 …………………………….. 2-27
Exhibit 2-7: 2012, Fertility Drugs Market, Share by Supplier………………………… 2-30
Exhibit 2-8: The R.G. Edwards Embryo Transfer Catheters…………………………. 2-32
Exhibit 2-9: The Classic Ultrasoft Embryo Transfer Catheters and Stylets……… 2-33
Exhibit 2-10: The DuoFertility Assisted Natural Conception System ……………….. 2-36
3. COMPANY PROFILES…………………………………………………………………….. 3-1
3.1 Actavis, Inc. …………………………………………………………………………… 3-1
3.2 Bayer AG………………………………………………………………………………. 3-4
3.3 Ferring Pharmaceuticals A/S……………………………………………………. 3-7
3.4 Johnson & Johnson………………………………………………………………… 3-8
3.5 Merck & Company, Inc. …………………………………………………………. 3-10
3.6 Merck KGaA………………………………………………………………………… 3-14
3.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries LTD ………. 3-16
APPENDIX: COMPANY LISTING